These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29718334)

  • 1. Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.
    Bruinstroop E; Dalan R; Cao Y; Bee YM; Chandran K; Cho LW; Soh SB; Teo EK; Toh SA; Leow MKS; Sinha RA; Sadananthan SA; Michael N; Stapleton HM; Leung C; Angus PW; Patel SK; Burrell LM; Lim SC; Sum CF; Velan SS; Yen PM
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2698-2706. PubMed ID: 29718334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver.
    Brouwers B; Schrauwen-Hinderling VB; Jelenik T; Gemmink A; Sparks LM; Havekes B; Bruls Y; Dahlmans D; Roden M; Hesselink MKC; Schrauwen P
    Am J Physiol Endocrinol Metab; 2018 Feb; 314(2):E165-E173. PubMed ID: 29118014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial.
    Jeong JY; Sohn JH; Baek YH; Cho YK; Kim Y; Kim H
    World J Gastroenterol; 2017 Aug; 23(32):5977-5985. PubMed ID: 28932090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities.
    Dong H; Lu F; Wang N; Zou X; Rao J
    Front Med; 2011 Sep; 5(3):288-93. PubMed ID: 21964711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus.
    Fan Y; Xiong W; Li J; Hu A; He Z; Zhang J; Zhou G; Yin Q
    Pharm Biol; 2018 Dec; 56(1):567-572. PubMed ID: 30460863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study.
    van den Berg EH; van Tienhoven-Wind LJ; Amini M; Schreuder TC; Faber KN; Blokzijl H; Dullaart RP
    Metabolism; 2017 Feb; 67():62-71. PubMed ID: 28081779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes.
    Brouwers B; Schrauwen-Hinderling VB; Jelenik T; Gemmink A; Havekes B; Bruls Y; Dahlmans D; Roden M; Hesselink MKC; Schrauwen P
    Clin Sci (Lond); 2017 Aug; 131(15):1905-1917. PubMed ID: 28620012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease.
    Vanjiappan S; Hamide A; Ananthakrishnan R; Periyasamy SG; Mehalingam V
    Diabetes Metab Syndr; 2018 Jul; 12(4):479-482. PubMed ID: 29402657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
    Sinha RA; Bruinstroop E; Singh BK; Yen PM
    Thyroid; 2019 Sep; 29(9):1173-1191. PubMed ID: 31389309
    [No Abstract]   [Full Text] [Related]  

  • 17. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway.
    Fan Y; He Z; Wang W; Li J; Hu A; Li L; Yan L; Li Z; Yin Q
    Biomed Pharmacother; 2018 Oct; 106():733-737. PubMed ID: 29990865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
    Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.